series-c-plus
Stage
4
Investors
About
Karyopharm Therapeutics is a commercial-stage pharmaceutical company focused on developing novel cancer therapies based on Selective Inhibitor of Nuclear Export (SINE) technology to target oncogenesis.
Explore Karyopharm Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.